touchPODCAST

Navigating the treatment of RRMM with BCMA-directed therapies: Updates from COMy, ASCO and EHA 2025

touchCONGRESS for touchHAEMATOLOGY and touchONCOLOGY

Listen to multiple myeloma expert Prof. Philippe Moreau review key data for BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy), American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) 2025 congresses. Prof. Moreau is then joined by fellow experts Dr Paola Neri and Prof. Hermann Einsele to discuss how these data may apply in clinical practice.

Overview

• Data reviews with Prof. Moreau
• Expert panel discussions with Prof. Moreau, Dr Neri and Prof. Einsele on the themes below

Clinical themes

• Approved BCMA-directed therapeutic approaches 
• Practical application of BCMA-directed therapies
• Future of treating RRMM: Emerging BCMA-directed therapies and combinations

The internationally renowned multiple myeloma expert faculty

• Prof. Philippe Moreau: Nantes, France

• Prof. Hermann Einsele: Würzburg, Germany

• Dr Paola Neri: Calgary, AB, Canada

This touchPODCAST is for HCPs outside of the USA. 

This activity is funded by an independent medical education grant from GSK.

This activity is provided by touchIME.
touchIME is an EBAC® accredited provider.

For further information, visit our website: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com

Advancing care for patients with infantile haemangiomas: Timing is key

touchEXPERT FOCUS for touchDERMATOLOGY

Listen to Prof. Ilona Frieden share expert insights on the clinical management of infantile haemangiomas, with a focus on timely referral and effective risk stratification. She also explores current and emerging treatment options and practical strategies to support families throughout a patient’s care journey. 

The expert:

• Prof. Ilona Frieden, University of California, San Francisco, CA, USA

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Pierre Fabre Pharmaceuticals, Inc.

This activity is jointly provided by USF Health and touchIME in collaboration with our education partner, Pediatric Dermatology Research Alliance (PeDRA).

For further information visit our website:

https://touchdermaime.org/

Incorporating ADCs into the treatment of mBC: Practical considerations for the community oncologist

touchIN CONVERSATION for touchONCOLOGY

Listen to two oncologists discuss the incorporation of antibody–drug conjugates (ADCs) into the treatment of metastatic breast cancer, tackling questions submitted by the oncology community. They discuss how treatment can be guided by biomarkers, give practical insights into creating a personalized care plan for patients, and share strategies for managing ADC-associated toxicities.

The experts

• Prof. Giuseppe Curigliano, European Institute of Oncology and University of Milan, Italy
• Dr Alison Conlin, Providence Cancer Institute, Portland, OR, USA

This touchPODCAST is for HCPs outside of the UK. 

This activity is funded by an independent medical education grant from Gilead Sciences, Inc.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information, visit our website: https://touchoncologyime.org/adcs-in-the-treatment-of-mbc/

 

Multidisciplinary management of TNBC Integrating immunotherapies for early and metastatic disease

touchEXPERT FOCUS for touchONCOLOGY

Listen to a series of short interviews with three leading experts discussing the application of immunotherapy in triple-negative breast cancer (TNBC). The experts explore the latest data and guideline recommendations for immunotherapy in early-stage and metastatic TNBC, and how to maximize treatment benefits. 

The experts:

• Prof. Sherko Kümmel – Kliniken Essen-Mitte, Essen, Germany
• Prof. Rebecca Dent – National Cancer Center Singapore, Singapore
• Prof. Peter Schmid – Barts Cancer Institute, London, UK

This touchPODCAST is for healthcare professionals outside of the UK.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. 

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:

https://touchoncologyime.org/management-of-tnbc-with-immunotherapy/

Applying immunotherapy in clinical practice for patients with early-stage NSCLC

touchEXPERT FOCUS for touchRESPIRATORY

Listen to Prof. Jonathan Spicer share expert insights on immunotherapy in early-stage non-small cell lung cancer (NSCLC). He explores current treatment strategies, highlights the role of neoadjuvant, perioperative and adjuvant approaches, and considers practical aspects of clinical implementation.

The expert

• Prof. Jonathan Spicer, McGill University, Montreal, Canada

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information, visit our website: https://touchrespiratoryime.org/touchexpert-focus-immunotherapy-early-stage-nsclc/

 

Applying immunotherapy in clinical practice for patients with early-stage NSCLC

touchEXPERT FOCUS for touchONCOLOGY

Listen to Prof. Jonathan Spicer share expert insights on immunotherapy in early-stage non-small cell lung cancer (NSCLC). He explores current treatment strategies, highlights the role of neoadjuvant, perioperative and adjuvant approaches, and considers practical aspects of clinical implementation.

The expert

• Prof. Jonathan Spicer, McGill University, Montreal, Canada

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information, visit our website: https://touchoncologyime.org/touchexpert-focus-immunotherapy-early-stage-nsclc/

 

Towards personalized care for people living with HIV: Supporting open dialogue and informed treatment choices

NEW touchCASES for touchINFECTIOUS DISEASES

Listen to  Prof. José Arribas, a leading HIV expert, and Ms Harriet Langanke, a journalist and HIV activist, discuss personalized care strategies for people living with HIV, focusing on three key concerns: weight gain, pill fatigue and treatment initiation.

The experts:

• Prof. José Arribas, University Hospital La Paz, Madrid, Spain,
• Ms Harriet Langanke, GSSG, Cologne, Germany

This touchPODCAST is for HCPs outside of the UK

This activity is funded by an independent medical education grant from Viiv Healthcare. This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information, visit our website: https://touchinfectiousdiseases.com

RET-positive NSCLC: Translating insights into targeted approaches

touchFOCUS for touchRESPIRATORY

In this concise interview, Dr Christine Bestvina discusses the key clinical questions surrounding currently approved RET inhibitors in NSCLC.

The expert:

• Dr Christine Bestvina - University of Chicago, Chicago, IL, USA
  

This touchPODCAST is for HCPs outside the UK. 

This activity is funded by an independent medical education grant from Rigel Pharmaceuticals Inc.

This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchrespiratory.com

RET-positive NSCLC: Translating insights into targeted approaches

touchFOCUS for touchONCOLOGY

In this concise interview, Dr Christine Bestvina discusses the key clinical questions surrounding currently approved RET inhibitors in NSCLC.

The expert:

• Dr Christine Bestvina - University of Chicago, Chicago, IL, USA
  

This touchPODCAST is for HCPs outside the UK. 

This activity is funded by an independent medical education grant from Rigel Pharmaceuticals Inc.

This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com

Advances in dry eye disease: From diagnosis to new treatment targets

touchEXPERT FOCUS touchOPHTHALMOLOGY

Listen to Dr Laura Periman share expert insights on dry eye disease. In this episode, she explores the pathophysiological mechanisms behind the condition, highlights key diagnostic tools, reviews current treatment options—including exciting advances in neuromodulation therapies—and discusses emerging targeted approaches shaping clinical management today.

 

The expert

• Dr Laura Periman, Periman Eye Institute, Seattle, WA, USA

This touchPODCAST is for HCPs outside of the UK. 

This activity is funded by an independent medical education grant from Alcon Vision, LLC.

The activity is jointly provided by USF Health and touchIME. 

For further information, visit our website: https://touchophthalmologyime.org/advances-in-dry-eye-disease/